Search results
Showing 1021 to 1035 of 2107 results for technology appraisal
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)
Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors.
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA1148)
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.
Macimorelin for diagnosing growth hormone deficiency (MIB320)
NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency .
How you can use our recommendations, tools and resources: maternity and neonatal health
How to use NICE guidance to reduce health inequalities during and after pregnancy.
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.